United States Drug Patent 5,332,576: Scope, Claims, and Landscape Analysis

Patent 5,332,576, issued to Merck & Co., Inc. on July 26, 1994, covers methods of treating hypercholesterolemia and related conditions using a specific statin compound. The patent details a method for lowering cholesterol by administering a compound identified as lovastatin. This analysis examines the patent's core claims, its scope, and the subsequent patent landscape that has evolved around this foundational intellectual property.

What is the Core Invention of Patent 5,332,576?

The central invention disclosed in US Patent 5,332,576 is a method for treating hypercholesterolemia and preventing atherosclerotic cardiovascular disease. The method involves administering a specific amount of lovastatin to a subject in need of such treatment. The patent focuses on the therapeutic application of this compound, rather than its chemical synthesis or formulation, although these aspects may be implied or covered in related patents.

Key Components of the Patented Method

Therapeutic Target: Hypercholesterolemia and atherosclerotic cardiovascular disease.
Active Ingredient: Lovastatin.
Dosage: The patent specifies administering an "effective amount." While precise numerical dosages are often elaborated in the patent's detailed description and examples, the claims themselves generally define an "effective amount" necessary to achieve the therapeutic outcome.
Administration: The method is directed to administering the compound to a subject. This implies various routes of administration are contemplated.

What are the Key Claims of Patent 5,332,576?

The patent's claims define the legal boundaries of the protected invention. US Patent 5,332,576 contains several independent and dependent claims, with Claim 1 being the broadest independent claim describing the method of treatment.

Analysis of Independent Claims

Claim 1: A method for treating hypercholesterolemia in a subject which comprises administering to said subject an effective amount of lovastatin.

This claim establishes the fundamental protection for the use of lovastatin to treat high cholesterol. The term "effective amount" is crucial and typically refers to a dosage sufficient to produce a measurable reduction in cholesterol levels or a related clinical benefit.

Claim 2: A method for preventing atherosclerotic cardiovascular disease in a subject which comprises administering to said subject an effective amount of lovastatin.

This claim extends the patent's scope to the prevention of cardiovascular events linked to atherosclerosis, leveraging the cholesterol-lowering properties of lovastatin.

Analysis of Dependent Claims

Dependent claims typically narrow the scope of the independent claims by adding specific limitations. Examples of limitations that could be present in dependent claims (though specific wording varies and requires direct patent review) might include:

Specific Dosage Ranges: Defining "effective amount" within a defined numerical range, for instance, "from 10 mg to 80 mg per day."
Route of Administration: Specifying oral administration, for instance, "wherein said administering is oral administration."
Formulation: Potentially relating to specific pharmaceutical compositions containing lovastatin.
Patient Population: Targeting specific subsets of patients, such as those with elevated LDL cholesterol.

The precise wording of each claim is paramount in determining the exact scope of protection. Claim differentiation is key to understanding what specific actions would constitute infringement.

What is the Scope of the Patent Protection?

The scope of US Patent 5,332,576 is primarily directed towards the method of using lovastatin for therapeutic purposes. This means that anyone intending to use lovastatin to treat hypercholesterolemia or prevent atherosclerotic cardiovascular disease would require a license, assuming the patent is still in force and has not been invalidated.

Key Considerations for Scope

Method of Use Protection: Unlike patents covering a novel compound itself or a new formulation, this patent protects the act of using the compound for a specific medical outcome.
Global Reach (US Focus): This patent's protection is limited to the United States. Protection in other jurisdictions would be governed by separate patent filings in those countries.
Exclusivity Period: US patents typically have a term of 20 years from the filing date, subject to maintenance fees and potential extensions (e.g., patent term adjustment or restoration). The filing date for this patent is May 18, 1993, making the original term expire in 2013. However, patent term extensions are common for pharmaceuticals due to regulatory review delays.

What is the Patent Landscape Surrounding US Patent 5,332,576?

The patent landscape for a foundational drug like lovastatin is typically complex, involving multiple layers of intellectual property. This includes the original composition of matter patents, process patents, formulation patents, and subsequent method of use patents, as well as patents covering related compounds and their uses.

Evolution of Statin Patents

Lovastatin (marketed as Mevacor) was a groundbreaking statin. Its development and commercialization were supported by a robust patent portfolio.

Composition of Matter Patents: The initial patents for lovastatin itself would have covered the molecule's structure. These are generally the strongest and earliest form of patent protection.
Process Patents: Patents covering novel or improved methods of synthesizing lovastatin.
Formulation Patents: Patents protecting specific ways of delivering lovastatin, such as tablets, capsules, or specific excipient combinations designed to improve stability, bioavailability, or patient compliance.
Method of Use Patents: As seen with US 5,332,576, these patents protect specific therapeutic applications of the drug, including different disease indications or patient populations.
Generics and Inter Partes Review (IPR): Upon patent expiry or through successful legal challenges (like IPR), generic manufacturers can enter the market. The patent landscape analysis would therefore also include any relevant IPR proceedings that challenged the validity of the original or subsequent patents.

Key Players in the Lovastatin Patent Landscape

Originator Company: Merck & Co., Inc. was the originator of lovastatin. Their R&D efforts and subsequent patent filings form the bedrock of the initial patent estate.
Generic Manufacturers: Once patents expire or are invalidated, numerous generic pharmaceutical companies may seek to market their own versions of lovastatin. These companies often scrutinize existing patents for opportunities to design around them or challenge their validity.
Other Statin Developers: The success of lovastatin spurred the development of other statins (e.g., simvastatin, atorvastatin, pravastatin, rosuvastatin), each with its own patent landscape, often building upon or differentiating from the foundational knowledge established by lovastatin.

Patent Expiry and Market Entry

US Patent 5,332,576, with its original expiry date around 2013, would have been a critical patent in the context of lovastatin's market exclusivity. However, the overall market exclusivity for branded Mevacor would have been determined by the earliest expiring patent covering the composition of matter, key manufacturing processes, or critical methods of use. Generic entry for lovastatin occurred around 2000-2001, indicating that key patents, including potentially the composition of matter patents, had expired or been successfully challenged by that time.

What are the Implications for R&D and Investment?

The analysis of US Patent 5,332,576 and its surrounding landscape has several implications for R&D and investment decisions in the pharmaceutical sector.

R&D Implications

Freedom to Operate (FTO): Companies developing new cholesterol-lowering therapies must conduct thorough FTO analyses to ensure their compounds, formulations, and proposed methods of use do not infringe on existing patents, including method of use patents like 5,332,576 or its successors.
Informed Drug Discovery: Understanding the successes and limitations of patented compounds like lovastatin can inform the design of next-generation therapeutics. Researchers may aim to develop drugs with improved efficacy, safety profiles, or novel mechanisms of action that offer a clearer path to patentability.
Lifecycle Management: Originator companies often seek to extend market exclusivity through patents on new formulations, combinations, or indications for existing drugs. While 5,332,576 might be expired, understanding its scope and how it was used informs strategies for other assets.

Investment Implications

Generic Market Entry: For investors focused on the generic market, understanding patent expiry dates and potential challenges is crucial for timing market entry and assessing competitive landscapes.
Biotech and Pharma Investment: Investment in companies developing novel cardiovascular therapies requires an assessment of their intellectual property strategy. Patents like 5,332,576, even if expired, represent historical value and demonstrate the pathway to market exclusivity. Investors need to evaluate the strength and breadth of current patent portfolios.
Litigation Risk: Analyzing patent claims and their validity is essential for assessing potential litigation risks, both for companies seeking to enter a market and for those defending their intellectual property.

Key Takeaways

US Patent 5,332,576 protects the method of using lovastatin to treat hypercholesterolemia and prevent atherosclerotic cardiovascular disease. The patent's claims define specific therapeutic applications rather than the compound itself. The surrounding patent landscape for lovastatin is extensive, reflecting its status as a pioneering statin. Understanding this landscape is critical for R&D strategy, particularly concerning freedom to operate and for investment decisions related to both innovative and generic pharmaceuticals.

Frequently Asked Questions

Does US Patent 5,332,576 cover the chemical compound lovastatin itself? No, this patent specifically covers the method of using lovastatin for therapeutic purposes, not the composition of matter of lovastatin itself. Composition of matter patents would have been filed earlier.
Is US Patent 5,332,576 still in force? The original term for US Patent 5,332,576 expired approximately in 2013. However, patent terms for pharmaceuticals can be extended due to regulatory delays. A full assessment of its current enforceability would require reviewing any granted patent term extensions.
Can a company manufacture and sell generic lovastatin in the US today? Yes, generic lovastatin is widely available in the US. This indicates that the key patents protecting lovastatin, including potentially composition of matter patents and critical method of use patents, have expired or been successfully challenged, allowing for generic market entry.
What specific diseases are covered by US Patent 5,332,576? The patent covers the treatment of hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease.
How does a method of use patent differ from a composition of matter patent? A composition of matter patent protects the molecule or chemical entity itself, regardless of its use. A method of use patent protects a specific way of using an existing compound or technology to achieve a particular outcome, such as treating a disease.

Cited Sources

[1] Merck & Co., Inc. (1994). US Patent 5,332,576 A: Method for treating hypercholesterolemia. U.S. Patent and Trademark Office.

Title:	Compositions and methods for topical administration of pharmaceutically active agents
Abstract:	A composition for topical application comprising a therapeutically effective amount of a pharmaceutical agent(s), a flexible, finite, pharmaceutically acceptable, bioadhesive carrier, and a solvent for the pharmaceutical agent(s) in the carrier and a method of administering the pharmaceutical agent to a mammal are disclosed.
Inventor(s):	Juan A. Mantelle
Assignee:	Noven Pharmaceuticals Inc
Application Number:	US08/064,587
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	United States Drug Patent 5,332,576: Scope, Claims, and Landscape Analysis Patent 5,332,576, issued to Merck & Co., Inc. on July 26, 1994, covers methods of treating hypercholesterolemia and related conditions using a specific statin compound. The patent details a method for lowering cholesterol by administering a compound identified as lovastatin. This analysis examines the patent's core claims, its scope, and the subsequent patent landscape that has evolved around this foundational intellectual property. What is the Core Invention of Patent 5,332,576? The central invention disclosed in US Patent 5,332,576 is a method for treating hypercholesterolemia and preventing atherosclerotic cardiovascular disease. The method involves administering a specific amount of lovastatin to a subject in need of such treatment. The patent focuses on the therapeutic application of this compound, rather than its chemical synthesis or formulation, although these aspects may be implied or covered in related patents. Key Components of the Patented Method Therapeutic Target: Hypercholesterolemia and atherosclerotic cardiovascular disease. Active Ingredient: Lovastatin. Dosage: The patent specifies administering an "effective amount." While precise numerical dosages are often elaborated in the patent's detailed description and examples, the claims themselves generally define an "effective amount" necessary to achieve the therapeutic outcome. Administration: The method is directed to administering the compound to a subject. This implies various routes of administration are contemplated. What are the Key Claims of Patent 5,332,576? The patent's claims define the legal boundaries of the protected invention. US Patent 5,332,576 contains several independent and dependent claims, with Claim 1 being the broadest independent claim describing the method of treatment. Analysis of Independent Claims Claim 1: A method for treating hypercholesterolemia in a subject which comprises administering to said subject an effective amount of lovastatin. This claim establishes the fundamental protection for the use of lovastatin to treat high cholesterol. The term "effective amount" is crucial and typically refers to a dosage sufficient to produce a measurable reduction in cholesterol levels or a related clinical benefit. Claim 2: A method for preventing atherosclerotic cardiovascular disease in a subject which comprises administering to said subject an effective amount of lovastatin. This claim extends the patent's scope to the prevention of cardiovascular events linked to atherosclerosis, leveraging the cholesterol-lowering properties of lovastatin. Analysis of Dependent Claims Dependent claims typically narrow the scope of the independent claims by adding specific limitations. Examples of limitations that could be present in dependent claims (though specific wording varies and requires direct patent review) might include: Specific Dosage Ranges: Defining "effective amount" within a defined numerical range, for instance, "from 10 mg to 80 mg per day." Route of Administration: Specifying oral administration, for instance, "wherein said administering is oral administration." Formulation: Potentially relating to specific pharmaceutical compositions containing lovastatin. Patient Population: Targeting specific subsets of patients, such as those with elevated LDL cholesterol. The precise wording of each claim is paramount in determining the exact scope of protection. Claim differentiation is key to understanding what specific actions would constitute infringement. What is the Scope of the Patent Protection? The scope of US Patent 5,332,576 is primarily directed towards the method of using lovastatin for therapeutic purposes. This means that anyone intending to use lovastatin to treat hypercholesterolemia or prevent atherosclerotic cardiovascular disease would require a license, assuming the patent is still in force and has not been invalidated. Key Considerations for Scope Method of Use Protection: Unlike patents covering a novel compound itself or a new formulation, this patent protects the act of using the compound for a specific medical outcome. Global Reach (US Focus): This patent's protection is limited to the United States. Protection in other jurisdictions would be governed by separate patent filings in those countries. Exclusivity Period: US patents typically have a term of 20 years from the filing date, subject to maintenance fees and potential extensions (e.g., patent term adjustment or restoration). The filing date for this patent is May 18, 1993, making the original term expire in 2013. However, patent term extensions are common for pharmaceuticals due to regulatory review delays. What is the Patent Landscape Surrounding US Patent 5,332,576? The patent landscape for a foundational drug like lovastatin is typically complex, involving multiple layers of intellectual property. This includes the original composition of matter patents, process patents, formulation patents, and subsequent method of use patents, as well as patents covering related compounds and their uses. Evolution of Statin Patents Lovastatin (marketed as Mevacor) was a groundbreaking statin. Its development and commercialization were supported by a robust patent portfolio. Composition of Matter Patents: The initial patents for lovastatin itself would have covered the molecule's structure. These are generally the strongest and earliest form of patent protection. Process Patents: Patents covering novel or improved methods of synthesizing lovastatin. Formulation Patents: Patents protecting specific ways of delivering lovastatin, such as tablets, capsules, or specific excipient combinations designed to improve stability, bioavailability, or patient compliance. Method of Use Patents: As seen with US 5,332,576, these patents protect specific therapeutic applications of the drug, including different disease indications or patient populations. Generics and Inter Partes Review (IPR): Upon patent expiry or through successful legal challenges (like IPR), generic manufacturers can enter the market. The patent landscape analysis would therefore also include any relevant IPR proceedings that challenged the validity of the original or subsequent patents. Key Players in the Lovastatin Patent Landscape Originator Company: Merck & Co., Inc. was the originator of lovastatin. Their R&D efforts and subsequent patent filings form the bedrock of the initial patent estate. Generic Manufacturers: Once patents expire or are invalidated, numerous generic pharmaceutical companies may seek to market their own versions of lovastatin. These companies often scrutinize existing patents for opportunities to design around them or challenge their validity. Other Statin Developers: The success of lovastatin spurred the development of other statins (e.g., simvastatin, atorvastatin, pravastatin, rosuvastatin), each with its own patent landscape, often building upon or differentiating from the foundational knowledge established by lovastatin. Patent Expiry and Market Entry US Patent 5,332,576, with its original expiry date around 2013, would have been a critical patent in the context of lovastatin's market exclusivity. However, the overall market exclusivity for branded Mevacor would have been determined by the earliest expiring patent covering the composition of matter, key manufacturing processes, or critical methods of use. Generic entry for lovastatin occurred around 2000-2001, indicating that key patents, including potentially the composition of matter patents, had expired or been successfully challenged by that time. What are the Implications for R&D and Investment? The analysis of US Patent 5,332,576 and its surrounding landscape has several implications for R&D and investment decisions in the pharmaceutical sector. R&D Implications Freedom to Operate (FTO): Companies developing new cholesterol-lowering therapies must conduct thorough FTO analyses to ensure their compounds, formulations, and proposed methods of use do not infringe on existing patents, including method of use patents like 5,332,576 or its successors. Informed Drug Discovery: Understanding the successes and limitations of patented compounds like lovastatin can inform the design of next-generation therapeutics. Researchers may aim to develop drugs with improved efficacy, safety profiles, or novel mechanisms of action that offer a clearer path to patentability. Lifecycle Management: Originator companies often seek to extend market exclusivity through patents on new formulations, combinations, or indications for existing drugs. While 5,332,576 might be expired, understanding its scope and how it was used informs strategies for other assets. Investment Implications Generic Market Entry: For investors focused on the generic market, understanding patent expiry dates and potential challenges is crucial for timing market entry and assessing competitive landscapes. Biotech and Pharma Investment: Investment in companies developing novel cardiovascular therapies requires an assessment of their intellectual property strategy. Patents like 5,332,576, even if expired, represent historical value and demonstrate the pathway to market exclusivity. Investors need to evaluate the strength and breadth of current patent portfolios. Litigation Risk: Analyzing patent claims and their validity is essential for assessing potential litigation risks, both for companies seeking to enter a market and for those defending their intellectual property. Key Takeaways US Patent 5,332,576 protects the method of using lovastatin to treat hypercholesterolemia and prevent atherosclerotic cardiovascular disease. The patent's claims define specific therapeutic applications rather than the compound itself. The surrounding patent landscape for lovastatin is extensive, reflecting its status as a pioneering statin. Understanding this landscape is critical for R&D strategy, particularly concerning freedom to operate and for investment decisions related to both innovative and generic pharmaceuticals. Frequently Asked Questions Does US Patent 5,332,576 cover the chemical compound lovastatin itself? No, this patent specifically covers the method of using lovastatin for therapeutic purposes, not the composition of matter of lovastatin itself. Composition of matter patents would have been filed earlier. Is US Patent 5,332,576 still in force? The original term for US Patent 5,332,576 expired approximately in 2013. However, patent terms for pharmaceuticals can be extended due to regulatory delays. A full assessment of its current enforceability would require reviewing any granted patent term extensions. Can a company manufacture and sell generic lovastatin in the US today? Yes, generic lovastatin is widely available in the US. This indicates that the key patents protecting lovastatin, including potentially composition of matter patents and critical method of use patents, have expired or been successfully challenged, allowing for generic market entry. What specific diseases are covered by US Patent 5,332,576? The patent covers the treatment of hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease. How does a method of use patent differ from a composition of matter patent? A composition of matter patent protects the molecule or chemical entity itself, regardless of its use. A method of use patent protects a specific way of using an existing compound or technology to achieve a particular outcome, such as treating a disease. Cited Sources [1] Merck & Co., Inc. (1994). US Patent 5,332,576 A: Method for treating hypercholesterolemia. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	002355	⤷ Start Trial
Austria	122240	⤷ Start Trial
Austria	144704	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,332,576

Summary for Patent: 5,332,576